Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

Next Previous
Trial Profile

TCR-a/b+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Haematopoietic stem cell therapy (Primary) ; Zoledronic acid (Primary) ; Antithymocyte globulin; Fludarabine; Melphalan; Mycophenolate mofetil; Tacrolimus; Tacrolimus; Thiotepa
  • Indications Acute myeloid leukaemia; Bone metastases; Cancer metastases; Ewing's sarcoma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Myeloproliferative disorders; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 06 Nov 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
  • 06 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
  • 06 Nov 2024 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top